Peptide Library

FDA-approved

Sexual & reproductive

Nafarelin

Evidence

FDA approved

Class

GnRH agonist

/

Nafarelin

KEY TAKEAWAY

Nafarelin is a synthetic GnRH agonist that is sprayed into the nose. It is sold as Synarel. The FDA approved nafarelin (Synarel) in 1990 for endometriosis and for central precocious puberty.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GnRH agonist

Approved for

Endometriosis and central precocious puberty

Key fact

The FDA approved nafarelin (Synarel) in 1990 for endometriosis and for central precocious puberty.

Route

Nasal spray, usually twice a day

Evidence strength

FDA approved

What it is

What it is

Nafarelin is a synthetic GnRH agonist that is sprayed into the nose. It is sold as Synarel.

How it works

How it works

It first stimulates and then desensitizes GnRH receptors, which lowers estrogen production.

Regulatory status

Regulatory status

The FDA approved nafarelin (Synarel) in 1990 for endometriosis and for central precocious puberty.

What it is used for

What it is used for

Endometriosis and central precocious puberty.

Side effects and risks

Side effects and risks

Hot flashes, reduced libido, bone density loss and nasal irritation are common.

Citations

Citations

U.S. FDA prescribing information for Nafarelin. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo